支气管动脉灌注化疗联合三维适形调强放疗治疗中央型非小细胞肺癌的临床研究

Clinical study of Bronchial arteral infusion combined with 3-dimensional conformal radiation therapy on advanced central nonsmall-cell lung cancer

目的评价支气管动脉灌注化疗联合三维适形放疗治疗中央型非小细胞肺癌的临床价值。方法 73例不能手术切除的中央型非小细胞肺癌患者分成2组,研究组:36例(鳞癌27例,腺癌9例)采用支气管动脉灌注化疗联合三维适形放疗方案,对照组:37例(鳞癌27例,腺癌10例)采用静脉化疗联合普通放疗方案。观察2组方案的有效率、临床收益率(CBR)、不良反应和生存期。结果两组近期有效率(CR+PR)分别为83.33%和62.16%(P=0.043),临床收益率分别为91.67%和72.97%(P=0.037),中位生存期分别为20.8个月和13.3个月,1、2年生存率分别为80.55%、63.86%和59.46%、40.54%(P<0.05)。结论支气管动脉灌注化疗联合三维适形放疗较静脉化疗联合普通放疗治疗中央型非小细胞肺癌可明显提高近期有效率、临床收益率和患者的1、2年生存率。

Objective To evaluate the efficacy of bronchial arteral infusion（BAI）combined with 3-dimensional conformal radiation therapy（3DCRT） for advanced central nonsmall-cell lung cancer（NSCLC）.Methods To retrospectively analyze the effectiveness of BAI combined with 3DCRT group and concurrent.chemoradiation group in the treatment of 73 patients with advanced central NSCLC.Results The effective rate（CR＋PR）、CBRof treatments group was83.33%、91.67%,median survival time was 20.8 months,1、2-year survival rate was 80.55%、63.86%;the effective rate（CR＋PR）、CBR of contral group was 62.16%、72.97%,median survival time was 13.3 months,1、2-year survival rate was 59.46%、40.54%;The effective rate、CBR and 1、2-year survival rate of treatments group were higher than those of contral group and there was significant difference betwween two groups（P0.05）.Conclusion The bronchial arteral infusion combined with 3DCRT can provide patients who had advanced central NSCLC with higher effective rate、CBR and 1、2-year survival rate compared with concurrent.chemoradiation.